Tandem Diabetes Care Announces Second Quarter 2020 Financial Results and Full Year 2020 Sales Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- Wall St set for higher open as AI stocks rise, oil slides
Tandem Diabetes (TNDM) Misses Q2 EPS by 21c, Revenues Beat; Offers FY20 Revenue Guidance Above Consensus, 3Q Revenues Outlook Below Consensus
July 30, 2020 4:21 PM EDTTandem Diabetes (NASDAQ: TNDM) reported Q2 EPS of ($0.45), $0.21 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $109.2 million versus the consensus estimate of $87.15 million.
We achieved our highest quarterly sales, successfully completed our first acquisition, and executed multiple meaningful agreements in support of our longer-term objectives in the second quarter, said John Sheridan,... More
